Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gemifloxacin: a new fluoroquinolone.

Expert opinion on pharmacotherapy - 1 May 2004

Blondeau Joseph M, Missaghi Bayan

Abstract excerpt

Gemifloxacin is a dual targeted fluoroquinolone with potent in vitro activity against Gram-positive, -negative and atypical human pathogens--pathogens considered to be important causes of community-acquired respiratory tract infections. Gemifloxacin demonstrates impressive minimal inhibitory concentrations (MIC 90 ) values against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Community-Acquired Infections
Share to Drug Evaluation, Preclinical
Share to Fluoroquinolones

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Guinea Pigs

Share to Intestines

Share to Multicenter Studies as Topic

Share to Naphthyridines

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 15155113
DOI: 10.1517/14656566.5.5.1117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gemifloxacin: a new fluoroquinolone.PMID 15155113Read ↗

Updated Review on Clinically-Relevant Properties of DelafloxacinSemantic proximity Read ↗

Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.Semantic proximity Read ↗

Gemifloxacin resistance in Mycobacterium tuberculosis without QRDR mutations in gyrA or gyrB: evidence for non-canonical resistance mechanisms.Semantic proximity Read ↗

The Fluoroquinolones: An Update for the Clinical MicrobiologistSemantic proximity Read ↗

Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer ActivitiesSemantic proximity Read ↗

In Vitro and In Vivo Antibacterial Activities of DC-159a, a New FluoroquinoloneSemantic proximity Read ↗

In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.Semantic proximity Read ↗

Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.Semantic proximity Read ↗

Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.Semantic proximity Read ↗

Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.Semantic proximity Read ↗

Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.Semantic proximity Read ↗

Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.